News for Charles River Laboratories Stock (CRL)

Bronstein, Gewirtz & Grossman, LLC Notifies Charles River Laboratories International, Inc. (CRL) Investors of Investigation

Business Wire • 02/24/23

CRL EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Charles River Laboratories International, Inc. Investors With Losses In Excess of $100K to Inquire About Securities Class Action Investigation – CRL

Business Wire • 02/23/23

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Charles River Laboratories International, Inc. and Encourages Investors with Losses to Contact the Firm

Business Wire • 02/23/23

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Charles River Laboratories International, Inc. and Encourages Investors with Losses to Contact the Firm

Business Wire • 02/22/23

Charles River Laboratories International, Inc. (CRL) Q4 2022 Earnings Call Transcript

Seeking Alpha • 02/22/23

Charles River (CRL) Q4 Earnings Top Estimates, Margins Dip

Zacks Investment Research • 02/22/23

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Charles River Laboratories International, Inc. (CRL) on Behalf of Investors

Business Wire • 02/22/23

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Charles River Laboratories International, Inc. (CRL) on Behalf of Investors

Business Wire • 02/22/23

The Law Offices of Frank R. Cruz Announces Investigation of Charles River Laboratories International, Inc. (CRL) on Behalf of Investors

Business Wire • 02/22/23

Charles River Laboratories (CRL) Q4 Earnings and Revenues Beat Estimates

Zacks Investment Research • 02/22/23

Charles River Dives As Monkey Investigation Hamstrings 2023 Outlook

Investors Business Daily • 02/22/23

Charles River Labs stock tumbles after DOJ subpoena disclosed, downbeat profit outlook

Market Watch • 02/22/23

Charles River Laboratories Announces Fourth-Quarter and Full-Year 2022 Results and Provides 2023 Guidance

Business Wire • 02/22/23

Charles River and Flagship's Pioneering Medicines Enter Agreement Leveraging AI-Powered Logica with Aim of Creating Novel Therapies for Unmet Medical Needs

Business Wire • 02/16/23

Charles River and Purespring Therapeutics Announce Gene Therapy Manufacturing Collaboration

Business Wire • 02/15/23

Charles River (CRL) Introduces Novel IgY-Based ELISA Kit

Zacks Investment Research • 02/14/23

Charles River Launches Novel IgY-based ELISA Kit for the Detection and Quantitation of Residual Host Cell Protein

Business Wire • 02/13/23

Charles River Laboratories Schedules Fourth-Quarter 2022 Earnings and 2023 Guidance Release and Conference Call

Business Wire • 02/09/23

Charles River Laboratories (CRL) to Report Q4 Results: Wall Street Expects Earnings Growth

Zacks Investment Research • 02/08/23

Charles River Laboratories International: A Great Business At A Decent Price

Seeking Alpha • 02/06/23

Charles River Laboratories Acquires SAMDI Tech

Business Wire • 01/30/23

Charles River's (CRL) New CDMO Tie-Up to Boost Clinical Trials

Zacks Investment Research • 01/20/23

Charles River (CRL) to Develop RNA-based Therapy With New Pact

Zacks Investment Research • 01/19/23

Charles River and Rznomics Announce RNA-based Anticancer Gene Therapy Manufacturing Alliance

Business Wire • 01/18/23

Charles River Launches CliniPrime Suite of GMP-Compliant Cellular Products

Business Wire • 01/16/23